 |
 |


Statistics misleading, some doctors say Relative numbers skew
benefit to look much larger
By John Crewdson Tribune senior
correspondent
March 15, 2002
Whether the breast cancer
death benefit attributed to mammography is 20 percent, 30 percent or
some other figure, those numbers represent the relative difference
in the risk of breast cancer death between large groups of women who
received regular mammograms for several years and equally large
groups who did not.
Even if the studies on which those
numbers are based, at least one of which is being questioned, prove
valid, the real benefit from mammography is much smaller than it may
appear.
Relative benefit "is OK for statistical inferences,"
says Donald Berry, the chief of biostatistics at the M.D. Anderson
Cancer Center in Houston, "but it is meaningless for a woman making
a screening decision. Absolute risk reduction is what
matters."
Numbers confuse even doctors
Relative
benefit, which makes an absolute difference appear larger, is
confusing even for physicians, much less their patients.
When
doctors in a study were told that a hypothetical medicine for high
blood pressure reduced a patient's chance of dying from heart
disease by 20 percent--the relative reduction in cardiac
deaths--they were nearly twice as likely to say they would prescribe
the drug as doctors who were told that it lowered the death rate
from 7.8 percent to 6.3 percent--the same benefit in absolute
terms.
Put another way, a 20 percent slice of a tiny pie is
still a very small piece of pie. And breast cancer, which annually
kills about 40,000 out of some 63 million American women over 40, is
a small pie compared with major killers like lung cancer, heart
disease and stroke.
The updated Swedish mammography trials to
be reported Saturday in The Lancet, show a current relative death
benefit of 20 percent among women who have mammograms. That's based
on the determination that out of 129,750 women who were invited to
begin having mammograms in the late 1970s and early 1980s, 511 died
of breast cancer over the next 15 years--a death rate of 0.4
percent.
In the comparison group of 117,260 women who were
not invited, there were 584 breast cancer deaths over the same
period--a death rate of 0.5 percent. That is, indeed, a 20 percent
relative benefit in favor of mammography. But the absolute
difference between the two groups after eight years of mammography
is seven deaths a year in a female population of
250,000.
Lars Werko, one of Sweden's best-known physicians,
believes "it is useless to look at mortality" when calculating the
benefits of mammography. "It is much better to look at how much the
thing prolongs life," Werko says. "The question is, is it worth
doing for such a short prolongation of life?"
Werko notes
that Finnish researchers attending a Swedish Cancer Society meeting
last month reported that that country's mammography screening
program had so far added between 10 and 12 days to the average
woman's life.
"It may be difficult to justify a screening
program . . . on the basis of the mortality reduction only," the
Finnish researchers concluded.
According to Berry, the latest
Swedish estimate of a 20 percent relative benefit means that the
average woman in her 40s will gain a little less than three extra
days of life. For women in their 50s the gain is a little more than
three days. For women in their 60s, it is eight extra
days.
Another way of measuring the benefit of mammography, or
any other medical intervention, is to calculate the number of
procedures needed to save one life, an approach favored by Dr.
Russell Harris, an internist and clinical epidemiologist at the
University of North Carolina School of Medicine.
Harris says
that when he takes time to explain the benefit of mammography to his
female patients in those terms, at least 1 in 10 chooses not to
undergo the procedure.
"I don't go at it saying mammography
is a bad thing," he says. "It's just that relative risk reduction is
not the way to go. It's necessary to understand the absolute risk.
All I'm arguing is that I want them to know that
number."
Simplifying the decision
Rather than tossing
around percentages and odds ratios, Harris asks his female patients
to imagine "a thousand people just like you. It's easier to
understand that way."
According to Harris's calculations, if
none of 1,000 50-year-old women ever has a mammogram, 13 will die of
breast cancer before they reach the age of 75--not a large number to
begin with because breast cancer, despite the attention it currently
is receiving, accounts for only about 2 percent of all
deaths.
Next, imagine that each of the 1,000 women has a
mammogram every year for the next 10 years. Assuming the Swedish
studies are valid, how will that affect the breast cancer death
toll?
Not by nearly as much as most women believe. Of the 13
women who would have died of breast cancer without mammograms, 10
still will die of breast cancer.
The absolute benefit of
mammography for women in their 50s, according to Harris, is three
lives saved--or, to be more precise, three breast cancer deaths
avoided--for every thousand women who have annual mammograms for 10
years, a total of 3,333 individual mammograms to prevent one
death.
If the 1,000 imaginary women in their 50s are replaced
by 1,000 women in their 60s, the number of breast cancer deaths
avoided increases to six.
A less conservative estimate, by
researchers at the University of California-San Francisco, suggests
between 2,700 and 5,400 individual mammograms are required to avoid
one death from breast cancer.
Ideally, saving even one life
at any cost is a worthy goal. In the real world of finite
health-care resources, the costs, both economic and psychic, must be
carefully considered.
"It is of course invidious to put a
price on a woman's life," says British surgeon Dr. Michael Baum,
"but one has to ask, could these large sums of money be redirected
both for service and research in such a way that more women would
benefit and fewer well women would be harmed?"
But Dr. Steven
Woolf, a professor of family practice at Virginia Commonwealth
University, notes that "the rest of us are interested in absolute
benefits not because of monetary concerns, but because of worries
about the harms of interventions. The cost is a side issue if the
intervention causes more harm than good."
A recent study in
The Lancet concluded that for every 10,000 mammograms given to
apparently healthy women, doctors will order an average of 647
"diagnostic" mammograms, a more painstaking, and expensive,
procedure to re-examine something that appeared suspicious the first
time around.
More tests follow procedure
Determining
which women have cancer, The Lancet said, also will require 358
breast examinations by ultrasound; 104 "aspiration" biopsies, in
which a long needle is used to remove fluid and cells from the area
of the breast with the apparent abnormality; 209 surgical biopsies,
in which part of the breast containing the abnormality is surgically
removed; and 500 additional doctor's office visits for physical
examinations or surgical consultations.
In the end, only
about 25 of the 1,000 women will have breast cancer, because the
great majority of the "abnormal" mammograms will prove to be false
positives. But the mammograms and the procedures they spawn will
have cost the health-care system about $350,000 for each breast
cancer death avoided, not counting the costs of treating those women
who actually do have cancer.
Copyright © 2002, Chicago
Tribune
|
 |
 |
 |

 Nancy Ryan, Advocate Posted June 2006

|
 |
Remember we are NOT Doctors
and have NO medical training.
This site is like an
Encylopedia - there are many pages, many links on many
topics.
Support our work with any size DONATION - see left
side of any page - for how to donate. You can help raise awareness
of CAM. | |